Something Is Changing in Viral Infant Bronchiolitis Approach
Authors:
Open Access
- 14 April 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 10, 865977
Abstract
Acute Viral Bronchiolitis is one of the leading causes of hospitalization in the first 12–24 months of life. International guidelines on the management of bronchiolitis broadly agree in recommending a minimal therapeutic approach, not recommending the use of bronchodilators. Guidelines, generally, consider bronchiolitis as a “unique disease” and this runs the risk of not administering therapy in some patients who could benefit from the use of bronchodilators, for instance, in those who will develop asthma later in their life and face first episode in the age of bronchiolitis. Today, there is growing evidence that bronchiolitis is not a single illness but can have different “endotypes” and “phenotypes,” based on age, personal or family history of atopy, etiology, and pathophysiological mechanism. There is evidence that some phenotypes of bronchiolitis are more strongly associated with asthma features and are linked to higher risk for asthma development. In these populations, possible use of bronchodilators might have a better impact. Age seems to be the main feature to suggest a good response to a bronchodilator-trial, because, among children > 6 months old with bronchiolitis, the presence of a subset of patients with virus-induced wheezing or the first episode of asthma is more likely. While waiting for new research to define the relationship between therapeutic options and different phenotypes, a bronchodilator-trial (using short-acting β2 agonists with metered-dose inhalers and valved holding chambers) seems appropriate in every child with bronchiolitis and age > 6 months.Keywords
This publication has 55 references indexed in Scilit:
- Bronchodilators for bronchiolitisCochrane Database of Systematic Reviews, 2014
- IL-27R–Mediated Regulation of IL-17 Controls the Development of Respiratory Syncytial Virus–Associated PathogenesisThe American Journal of Pathology, 2014
- Duration of symptoms of respiratory tract infections in children: systematic reviewBMJ, 2013
- A genome-wide association study identifies CDHR3 as a susceptibility locus for early childhood asthma with severe exacerbationsNature Genetics, 2013
- Oral Dexamethasone for Bronchiolitis: A Randomized TrialPediatrics, 2013
- Viral Etiologies of Infant Bronchiolitis, Croup and Upper Respiratory Illness During 4 Consecutive YearsThe Pediatric Infectious Disease Journal, 2013
- Prospective Multicenter Study of Viral Etiology and Hospital Length of Stay in Children With Severe BronchiolitisArchives of Pediatrics & Adolescent Medicine, 2012
- IL-17–Induced Pulmonary Pathogenesis during Respiratory Viral Infection and Exacerbation of Allergic DiseaseThe American Journal of Pathology, 2011
- Predictors of respiratory failure among previously healthy children with respiratory syncytial virus infectionThe American Journal of Emergency Medicine, 2011
- Effects of Nonstructural Proteins NS1 and NS2 of Human Respiratory Syncytial Virus on Interferon Regulatory Factor 3, NF-κB, and Proinflammatory CytokinesJournal of Virology, 2005